Research Alliance Corp. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Las vegas--(business wire)--research alliance corp. ii (the “company”) (nasdaq: racb), a special purpose acquisition company, today announced that, the company will redeem all of its outstanding shares of class a common stock, par value $0.0001, issued by the company in its initial public offering (the “public shares”), effective as of the close of business on december 2, 2022, if at the company’s special meeting on december 2, 2022 the requisite stockholders of the company approve (the “stockholder approval”) the proposed amendment to the company’s amended and restated certificate of incorporation (the “charter amendment”) and the proposed amendment to that certain investment management trust agreement, dated march 17, 2021 (the “trust agreement”), by and between the company and continental stock transfer & trust company, a new york limited purpose trust company, as trustee (“continental”), in each case, as described in the definitive proxy statement filed by the company with the securities and exchange commission on november 7, 2022, as may be amended or supplemented from time to time...

Indianapolis--(business wire)--point biopharma inc. (point), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, announced today that the u.s. nuclear regulatory commission (nrc) has issued a materials license for its new production facility located in indianapolis, indiana. point is currently finishing renovations to its 80,000-square-foot radiopharmaceutical manufacturing center which, when complete, will make it one of the largest, state-of-the-art, good manufacturing practices (gmp) radioligand manufacturing facilities in the world. the nrc materials license authorizes the handling of nuclear material in chemical and/or physical form, enabling point to begin work with a wide variety of radioisotopes on-site and complete testing and qualification of its operations...

New york, march 27, 2021 /prnewswire/ --  juan monteverde , founder and managing partner at monteverde & associates pc, a national securities firm rated top 50 in the 2018 and 2019 iss securities class action services report and headquartered at the empire state building in new york city, is investigating research alliance corp. i ("raca" or the "company") (raca) relating to its proposed merger with point biopharma, inc. under the terms of the agreement, raca will acquire point through a reverse merger, with point emerging as a publicly traded company. the investigation focuses on whether research alliance corp. i and its board of directors violated securities laws and/or breached their fiduciary duties to the company by 1) failing to conduct a fair process, 2) whether the transaction is properly valued, and 3) whether all material information has been disclosed.

Las vegas--(business wire)--research alliance corp. ii (nasdaq:racb) (the “company”) announced today that on march 22, 2021 it closed its initial public offering of 14,950,000 shares of class a common stock, including 1,950,000 shares issued pursuant to the exercise by the underwriters of their over-allotment option. the offering was priced at $10.00 per share, resulting in gross proceeds of $149,500,000. the company, sponsored by ra capital management, l.p., is led by chairman and ceo peter kolchinsky phd, cio matthew hammond, phd and cfo tess cameron. the company is a blank check company formed for the purpose of effecting a business combination with one or more businesses in the healthcare industry...

NEW YORK, March 27, 2021 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Research Alliance Corp. I ("RACA" or the "Company") (RACA) relating to its proposed merger with POINT Biopharma, Inc. Under the terms of the agreement, RACA will acquire POINT through a reverse merger, with POINT emerging as a publicly traded company. The investigation focuses on whether Research Alliance Corp. I and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, 2) whether the transaction is properly valued, and 3) whether all material information has been disclosed.